Insights in Leukemia Treatment

Abstract

Leukemia is a group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. Leukemia is generally of 4 Types, which may be lymphocytic or myelogenous. Present Review describes the types of Leukemia, various treatments in past, present and future advances. Cancer being the yet to be solved factor in medical sciences, recent research have enormous use of technology equipped with crystal clear knowledge.

Keywords

Leukemia, Chemotechniques, Metacytes, Blood Transplantation, Biomarkers

Introduction

Leukemia may be acute or chronic. Acute leukemia gets worse very fast and Chronic leukemia gets worse slowly and may not cause symptoms for years. 4 different Types of Leukemia include: Acute lymphoblastic leukemia, Acute myelogenous leukemia, Chronic lymphocytic leukemia [1], Chronic myelogenous leukemia [2]. Cancer Therapies have been recently showing progress with time and increasing complications that begin with life style issues [3]. Malignant cells of Leukemia travel to various body organs especially cell and infest them such as Nervous System [4,5], Blood [6], Plasma [7,8], Hairy Cell [9] and other diseases ontologically can be expressed [10].

Treatment Strategies

Leukemia accounts for many treatment strategies such as use of Biomarker Cells example: Circulating m- RNA Biomarkers [11,12], Bone Marrow Transplantation Strategies [13,14], Stem Cell Chemotechniques [15,16], Immunomodulatory therapies [17-19], Blood Transplantation Therapy (Special Case in HIV associated Leukemia) [20], Tomographic Diagnosis Techniques [21], Drug Combination Therapies [22,23] etc.

Prospects for Future Advances

Future advances have been rapidly developing for the Quality progress of metacytes to the various radiation techniques, Laser Non invasive Surgeries, Molecular Targeted Therapies [24], new advances in Chronic Lymphocytic Leukemia [25], CAR T-cell therapy, Protein Targeted Therapies, etc. But recent times show major problems regarding the drug combinations and a combat is required essentially [26].

Conclusion

Scientists are progressively enhancing in this version for the better clinical studies with key insights [27]. Proper life style with well comforted diet including major Exercise, Yoga and food intake management with regular Doctor checkup may reduce the Level of cancer effectiveness up to some extent.

References

1. Jonsson V et al. Chronic Lymphocytic Leukemia, Advantages of Monoclones?. J Leuk (Los Angel). 2014;2:142.
2. Niermann C et al. The History of Lymphoma Classifications with Special Consideration of Cutaneous Lymphomas. J Leuk (Los Angel). 2013;1: 112.
3. Bisen PS. Cancer Therapy: An Overview. J Cancer SciTher. 2013;6:e130.
4. Grisold W et al. Leukemia and the Peripheral Nervous System: A review. J Leuk (Los Angel). 2014;2:162.
5. Imane T et al. Plasmocytoid Dendritic Cells Leukemia: A Rare Presentation. J Leuk (Los Angel). 2014;2:131.
6. Miyauchi J. Spontaneous Remission of Transient Leukemia in Down Syndrome: Extrinsic or Intrinsic Mechanism?. J Leuk (Los Angel). 2014;2:149.
7. Alessandra GM et al. Plasma Cell Leukemia Remains Like an Incurable Disease? A Rare Presentation of an Aggressive Case of Secondary Plasma Cell Leukemia. J Leuk (Los Angel). 2015;2:157.
8. Adams J and Zhou J. Plasma Cell Myeloma with Unusual Expression of CD19, CD10, CD45 and Surface Light Chain in a Human Immunodeficiency Virus Positive Patient. J Leuk (Los Angel). 2013;1:126.
9. Robak T. New Therapies for Hairy Cell Leukemia. J Leuk (Los Angel). 2014;2:e106.
10. SanyaoluAAn et al. Otological Diseases in Patients with Chronic Myeloid Leukemia. J Leuk (Los Angel). 2014;2:128.
11. Cui Z and Lin D. Circulating miRNAs: Potential Biomarkers for Diagnosis and Prognosis Prediction of Hematological Malignancies. J Leuk (Los Angel). 2014;2:140.
12. Ibrahim L et al. CD49d and CD26 are Independent Prognostic Markers for Disease Progression in Patients with Chronic Lymphocytic Leukemia. J Leuk (Los Angel). 2015;3:173.
13. Ikehara S. Advances in Leukemia Treatment with Bone Marrow Transplantation. J Leuk (Los Angel). 2014; 2:136.
14. Khoj L et al. A Case of Dengue Fever-Induced Severe Aplastic Anemia Salvaged by Allogeneic Bone Marrow Transplant. J Leuk (Los Angel). 2013;1:120
15. Jaglowski SM et al. Barriers to Proceeding to Reduced-Intensity Allogeneic Stem Cell Transplant in Chronic Lymphocytic Leukemia. J Leuk (Los Angel). 2013;1:121.
16. Kamel AM et al. Gamma/IL10 Ratio Production in Response to Host Antigens may Predict Acute Graft Versus Host Disease after Allogeneic Stem Cell Transplantation from a Sibling. J Leuk (Los Angel). 2013;1:111.
17. Bar M. Adoptive Immunotherapy for Acute Myeloid Leukemia: From Allogeneic Hematopoietic Cell Transplantation to CAR T Cells. J Leuk (Los Angel). 2014;2:134.
18. Bedewy AML and El-Maghraby SM. What Determines the Response to Immunomodulatory Therapy in Multiple Myeloma?. J Leuk (Los Angel). 2014;2:143.
19. Fuchs O et al. Lenalidomide Therapy of Myelodysplastic Syndromes. J Leuk (Los Angel). 2013;1:104.
20. Petz LD. Cure of HIV-Infected Leukemia Patients with Cord Blood Transplantation. J Leuk (Los Angel). 2014;2:145.
21. Ríos-Tamayo R et al. Positron Emission Tomography with Integrated Computed Tomography in Multiple Myeloma: A Silent Revolution. J Leuk (Los Angel). 2015;3:e112.
22. Barth BM et al. Combinatorial Efficacy of NanoliposomalCeramide and the Antioxidant 7,8-Benzoflavone for Acute Myeloid Leukemia. J Leuk (Los Angel). 2015;2:152.
23. Brown TJ et al. Therapeutic Combination of NanoliposomalSafingol and NanoliposomalCeramide for Acute Myeloid Leukemia. J Leuk (Los Angel). 2013;1:110.
24. Tayyab M et al. Distinct Gene Mutations, their Prognostic Relevance and Molecularly Targeted Therapies in Acute Myeloid Leukemia (AML). J Cancer SciTher. 2014;6:337-349.
25. Jeyakumar G and Ferrajoli A. New Therapeutic Advances in Chronic Lymphocytic Leukemia. J Leuk (Los Angel). 2014;2:144.
26. Sisay EA et al. Drug Related Problems in Chemotherapy of Cancer Patients. J Cancer SciTher . 2015;7:055-059.
27. Feng Y et al. Cancer Chemotherapy: Time for New Solution. Chemotherapy. 2014;3:130.